` Comparison: SAN vs MRK - Alpha Spread

SAN
vs
MRK

Over the past 12 months, SAN has underperformed MRK, delivering a return of -20% compared to the MRK's +35% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
SAN
MRK
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

SAN Intrinsic Value
LOCKED
Unlock
MRK Intrinsic Value
LOCKED
Unlock
Company Last Price Intrinsic Value DCF Value Multiples-Based Value Wall St Target
Sanofi SA
PAR:SAN
82.5 EUR
Merck & Co Inc
NYSE:MRK
120.84 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
SAN, MRK

SAN
MRK
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Sanofi SA
Revenue
Merck & Co Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
SAN, MRK

SAN
MRK
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Sanofi SA
PAR:SAN
Merck & Co Inc
NYSE:MRK
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

SAN
72.1%
MRK
81.5%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

Operating Margin

SAN
21.6%
MRK
41.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

Net Margin

SAN
16.7%
MRK
28.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

FCF Margin

SAN
23.4%
MRK
19%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

ROE

SAN
10.5%
MRK
36.9%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

ROA

SAN
6%
MRK
14.4%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

ROIC

SAN
7.8%
MRK
21.4%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

ROCE

SAN
10%
MRK
27.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Sanofi SA
Merck & Co Inc

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
SAN, MRK

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SAN, MRK

Performance Gap Between SAN and MRK
LOCKED
Unlock

Performance By Year
SAN, MRK

Loading
SAN
MRK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare SAN to other stocks
JNJ
Johnson & Johnson
More expensive
vs SAN
AZN
AstraZeneca PLC
More expensive
vs SAN
GILD
Gilead Sciences Inc
More expensive
vs SAN
PFE
Pfizer Inc
More expensive
vs SAN
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett